Forbes July 16, 2024
Niven R. Narain, Ph.D., President & CEO, BPGbio.
The promise of AI in drug discovery has fueled big business for the pharmaceutical industry with new AI drug companies smashing funding records one after another and new partnerships between big pharma and AI startups announced nearly every month.
To date, most of the focus on AI’s power revolves around its ability to enable the discovery of new drug targets. This only scratches the surface of what it takes to develop a new medicine, and the hype around AI as a magic bullet misses the bigger opportunity, which is to use AI to guide every stage of the drug discovery process.
With only about 12% of drugs that enter clinical trials ultimately...
Today's Sponsors
Today's Sponsor